GLYCOVAX is a European Training Network (ETN) funded in the framework of H2020 Marie Skłodowska- Curie ITN programme. The GLYCOVAX network aims at the education of promising young scientists who will learn how to rationally design well-defined and innovative glycoconjugate vaccines to improve current preventive therapies and tackle unmet medical needs. The project is based on a profound interaction between the academic and industrial sectors, involving 8 academic groups and 2 industrial partners. In this highly multidisciplinary environment 14 Early Stage Researchers ESRs are trained in the growing field of glycoscience and vaccinology, enriching their skills and combining different state-of-the-art methodologies for the rational design of innovative glycoconjugates.

Glycoconjugate vaccines represent the key for success of vaccination in children. Combination of novel approaches for glycan synthesis and site-selective conjugation methods now gives access to conjugates defined in sugar component and attachment site, thus leading to robust structure-immunogenicity relationship. By combining the beneficiaries’ expertise in carbohydrate synthesis, bioconjugation, high throughput screening, structural glycobiology, vaccinology and immunology, together with the experience in project management, GLYCOVAX creates a multidisciplinary environment where 14 young researchers will contribute to develop a novel route towards improved, safer and better characterized glycoconjugate vaccines, and contemporarily acquire transferable skills which will lead them to become the new leaders of academic or industrial research.

	IMPACT Glycoconjugate vaccines represent one of the most effective drugs ever discovered. Read more
	OBJECTIVES The main objective is to train young scientists in rational design of glycoconjugates. Read more
	BACKGROUND Together with hygiene, vaccines have made possible a great revolution in the 20th century, saving millions of lives. Read more